<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIM: The aim of the present observational study was to evaluate the diagnostic accuracy of CEA, CA 19-9 and CA 72-4 in patients with <z:e sem="disease" ids="C0021843" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">bowel obstruction</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: One-hundred three patients admitted to an emergency unit with clinical and radiological signs of <z:e sem="disease" ids="C0021843" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">intestinal occlusion</z:e> of unknown origin were prospectively studied </plain></SENT>
<SENT sid="2" pm="."><plain>Patients submitted to emergency surgery were excluded </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients underwent standard diagnostic procedures and serological assay of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> markers </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">Colorectal cancer</z:e> was diagnosed in 22 patients (21.4%), while 81 patients (78.6%) presented a benign condition </plain></SENT>
<SENT sid="5" pm="."><plain>The sensitivity of CEA, CA 19-9 and CA 72-4 for <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> was 36.4%, 31.8% and 9.1%, respectively </plain></SENT>
<SENT sid="6" pm="."><plain>Marker specificity was 91.4%, 90.1% and 95.1%, respectively </plain></SENT>
<SENT sid="7" pm="."><plain>The combination of CEA and CA 19-9 increased the sensitivity to 45.5% but decreased the specificity to 83.9% </plain></SENT>
<SENT sid="8" pm="."><plain>The overall accuracy was 79.6%, 77.7% and 76.7%, respectively </plain></SENT>
<SENT sid="9" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> positive <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cases had advanced disease </plain></SENT>
<SENT sid="10" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients with CEA levels &gt;10 ng/mL or CA 19-9 &gt;100 U/mL had <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS: Even in a highly selected population, <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> marker sensitivity was rather low and specificity incomplete </plain></SENT>
<SENT sid="12" pm="."><plain>However, elevated levels may guide the diagnostic and therapeutic course in patients with obstructing <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
</text></document>